The Nb-TriTE is the first proposed Nb-only candidate to simultaneously target CD3ε, solid tumor site and immune checkpoint, while this Nb-TriTE format differs from previously reported formats, such as TriTE [47], TriTAC [48, 49], DARPin [34], CiTE [33] and other trispecific antibodies for cancer immunotherapy [46]. The gene discussed is CD3E; the disease is cancer.